FAKTOR-OPTIONSSCHEIN - ZEALAND PHARMA | Delayed Börse Stuttgart 11:59:04 2024-06-06 am EDT | ||
| 7.86 EUR | +19.82% |
|
| Current month | -11.95% | ||
| 1 month | -12.06% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-06 | 7.86 | +19.82% |
| 24-06-05 | 6.56 | -0.91% |
| 24-06-04 | 6.62 | -16.94% |
| 24-06-03 | 7.97 | +6.98% |
| 24-05-31 | 7.45 | +14.97% |
Delayed Quote Börse Stuttgart
Last update June 06, 2024 at 11:59 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | ME9MAF |
| ISIN | DE000ME9MAF4 |
| Date issued | 2024-03-05 |
| Strike | 407.1 kr |
| Maturity | Unlimited |
| Parity | 4.19 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.09 € |
|---|---|
| Lowest since issue | 5.74 € |
| Spread | 0.04 € |
| Spread % | 0.51% |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
610.5
DKK
Average target price
785.6
DKK
Spread / Average Target
+28.68%
- Stock Market
- Certificates
- Certificat
